Market Overview

BlackThorn Therapeutics Announces Exclusive Licensing Agreement and Extension of Key Collaboration With Yale University


First Publication Emerges from Company's Multi-year Research
Collaboration with Yale's Division of Neurocognition, Neurocomputation,
and Neurogenetics

BlackThorn Therapeutics, a clinical-stage biopharmaceutical company
discovering and developing targeted treatments for neurobehavioral
disorders, today announced that it is entering into an exclusive
licensing agreement with Yale University School of Medicine as part of
its ongoing multi-year collaboration with Yale's Division of
Neurocognition, Neurocomputation, and Neurogenetics (N3). With the goal
of advancing the understanding of the neurobiological basis of
dysregulated mood and behavior, BlackThorn is licensing GEMINI-DOT (Gene
Expression Mapping Integrated with Neuro-Imaging for Discovery Of
Therapeutics), an innovative technology that was co-developed by
BlackThorn and professors Alan Anticevic, Ph.D., and John Murray, Ph.D.,
of Yale University.

The core innovation of GEMINI-DOT is the ability to bi-directionally map
gene expression patterns and neuroimaging features to optimize the
selection of drug targets and clinical populations. The science behind
this technology was featured in a study led by Dr. Murray and published
in the September issue of Nature Neuroscience. This study
characterizes the pattern of brain-wide gene transcriptomics in humans
in relation to non-invasive neuroimaging and, consequently, provide a
quantitative bridge between genetic expression patterns in the human
brain and neuroimaging features. Read Yale University's news release
about GEMINI-DOT and the published paper here.

"Progress toward novel therapeutics for CNS disorders has been hampered
by a poor understanding of target patient populations and an inability
to ground discovery and development in the underlying pathophysiology,"
said Bill Martin, Ph.D., chief scientific officer of BlackThorn
Therapeutics. "We believe that mapping specific neural patterns onto
specific receptor gene expression profiles represents a significant
advance for the field of clinical neuroscience. BlackThorn's data-driven
approach to drug development aligns with the work that N3 is doing. We
look forward to continuing to identify and validate neuromarkers of
behavioral variation in collaboration with Drs. Murray and Anticevic."

About BlackThorn Therapeutics, Inc.

BlackThorn Therapeutics is a clinical-stage biopharmaceutical company
dedicated to transforming the lives of people with neurobehavioral
disorders. BlackThorn has created a robust pipeline of first-in-class
and potentially best-in-class treatments. The company uses data-driven
approaches to create a unique understanding of the core underlying
pathophysiology of neurobehavioral disorders and applies these insights
to generate objective neuromarkers that support target identification,
patient stratification and clinical trial design. BlackThorn
Therapeutics is headquartered in San Francisco, Calif. For more
information, please visit

View Comments and Join the Discussion!